All In Biotech

Drug Trial Radar · NCT07441278

A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

177

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Sep 14, 2028

Study completion Dec 14, 2028

Sponsor

Lead sponsor
NS Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Nippon Shinyaku Co., Ltd.
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Conditions

  • Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Interventions

  • NS-863 Low DoseDrug

    NS-863 is an orally administered drug.

  • NS-863 High DoseDrug

    NS-863 is an orally administered drug.

  • PlaceboOther

    An orally administered NS-863 matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in pulmonary vascular resistance (PVR) at week 24Time frame: From baseline to week 24
  2. Number of participants who experienced an adverse event (AE) up to approximately 24 weeks.Time frame: From baseline to week 24

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • StatCare Pulmonary Consultants, PLLC

    Knoxville, Tennessee · Recruiting

  • Hospital of the University of Occupational and Environmental Health

    Kitakyushu, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.